Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244450 | 0.87 | RAB9A (0.60) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5155914 | 0.81 | MAPT (0.61) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2190235 | 0.80 | MAPT (0.60) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2062399 | 0.80 | MAPT (0.60) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4268370 | 0.80 | MAPT (0.56) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28522272 | 0.80 | MAPT (0.56) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2247322 | 0.79 | RAB9A (0.75) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10519938 | 0.78 | RAB9A (0.61) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10943282 | 0.78 | RAB9A (0.83) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2242707 | 0.77 | RAB9A (0.67) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221689-A | Crystal form of anti-hepatitis B compound and preparation method and application thereof | 齐鲁制药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117136187-A | Novel anti-hepatitis B compound | 上海齐鲁制药研究中心有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| US-5347008-A | Thio(cyclo) alkanepolycarboxylic acids containing heterocyclic substituents | CIBA-GEIGY CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| US-5152929-A | Corrosion inhibitors for water systems | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
| US-3933841-A | ANTHELMINTICS | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | KMT2A 4282/4885MAPT 1807/4885NPC1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.